Psoriasis Genetic Markers for Diagnostic Reliability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack reliable genetic markers for diagnosing and treating psoriasis, leading to ineffective therapeutic strategies and healthcare decisions, as existing associations are inconsistent and require further data for conclusive evidence.

Innovation Solution

Identification of specific single nucleotide polymorphisms (SNPs) and haplotypes associated with psoriasis, which can be used to design diagnostic and therapeutic agents, predict disease risk, and determine patient responses to treatments, enabling personalized medicine approaches.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current genetic association methods are used for psoriasis diagnosis, then diagnostic capability is limited, but reliability of genetic markers is insufficient

Engineering Contradiction:

Improvereliability of genetic markersVSAvoiddiagnostic capability

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent combines multiple genetic markers (HLA-Cw*06:02 allele with other susceptibility loci) into an integrated diagnostic approach. This merging of multiple markers increases both the reliability and precision of psoriasis diagnosis compared to using single markers alone, as the combined genetic profile provides more comprehensive disease prediction capability

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If existing genetic associations are used for treatment decisions, then therapeutic strategies are generic, but consistency of associations is insufficient

Engineering Contradiction:

Improveconsistency of genetic associationsVSAvoidpersonalized treatment capability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by identifying specific genetic profiles (HLA-Cw*06:02 allele and other susceptibility loci) that correspond to different psoriasis subtypes and treatment responses. This allows treatment strategies to be tailored to the specific genetic characteristics of each patient, providing consistent and reliable personalized medicine approaches rather than generic treatments

Inventive Principle:

Principle #3Local quality

3Measurement precision

If more genetic data is collected for conclusive evidence, then measurement precision improves, but loss of time increases

Engineering Contradiction:

Improveconclusive evidenceVSAvoidtime for data collection

Core Design Contradiction:

Measurement precisionVSLoss of time

Solution Approach 1:

The patent performs preliminary action by pre-identifying and validating the HLA-Cw*06:02 allele and other susceptibility loci as reliable psoriasis markers through prior genome-wide association studies. This preliminary validation allows clinicians to use these established markers for rapid diagnosis without needing to collect and analyze extensive additional genetic data, thus reducing time loss while maintaining measurement precision

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS11008618B2Genetic polymorphisms associated with autoinflammatory diseases, methods of detection and uses thereof

Publication Date: 2021.05.18 CELERA CORP

AI summary

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoinflammatory diseases such as psoriasis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.